Is Chinese Biopharma a Role Model for Reform and Innovation?

Update: 2016-12-06

Description

Once known for producing generic drugs and performing contract research for Western pharmaceutical companies, China’s biopharmaceutical industry today is marked by investments in research and development by homegrown companies that are driving the sector to new levels of innovation and growth.

In this podcast, Nick Leung, Franck LeDeu and Fangning Zhang discuss whether China’s biopharma sector could become a role model for reform and innovation for the rest of the economy. Franck and Fangning are Partners with McKinsey’s Healthcare Practice in China. Nick is Managing Partner of McKinsey’s Greater China Practice.

Comments

In Channel

What is China’s biggest economic challenge for the next 20 years?

2021-03-1031:11

When will the Chinese economy get back to normal?

2021-02-2330:27

Has COVID-19 infected the Chinese private equity industry?

2020-09-0424:19

Is Chinese industry emerging from COVID-19 stronger than ever?

2020-06-0530:27

Has COVID-19 changed the Chinese consumer for good?

2020-05-2831:43

How COVID-19 is fast-forwarding 5 key trends in China

2020-05-0634:48

What’s driving the Chinese economy in 2020?

2020-01-2427:01

Has China reached peak integration with the world?

2019-07-0231:12

How confident is the Chinese consumer?

2019-06-1027:07

The state of the Chinese economy

2019-03-0621:48